<html>
<head>
  <title>SARS-CoV-2 Nucleocapsid (N) gene D3L literature reference collection</title>
  <link rel="stylesheet" href="constellations.css">
</head>
<body>
<h1><a href="front.html">SARS-CoV-2</a> <a href="N.html">Nucleocapsid (N)</a> gene <span class="constellation">N:p.D3L</span> literature reference collection</h1>
<div class="effect_section"><h2 id="subgenomic_RNA_expression">Subgenomic RNA expression</h2>
<ul class="lit_list">
<li class="lit_item"><span class="lit_summary"> A noncanonical subgenomic RNA which could represent ORF9b is significantly enriched (~16x) in B.1.1.7 SARS-CoV-2 infections,  potentially as a result of a triple nucleotide mutation leading to amino acid substitution D3L  in nucleocapsid in this lineage which increases complementarity with the genomic leader sequence. <br/> (<a href="https://doi.org/10.1101/2021.03.02.433156" class="lit_link">Parker et al. (2021)</a>)</span></li>
</ul></div>
<div class="effect_section"><h2 id="variant_linear_antibody_epitope_effects">Variant linear antibody epitope effects</h2>
<ul class="lit_list">
<li class="lit_item"><span class="lit_summary"> At the epitope level, the D3L mutation reduces PIWAS signal in 1.5% of COVID patients (outliers reduce from 2.1% in wild type to 0.5% in mutant).<br/>In 3 of these patients (0.5% of the population), that alteration represents the strongest antigen signal and substantially reduces the PIWAS antigen score. In the B1.1.7 lineage this is largely counteracted by the S235F mutation, which increases epitope and antigen scores significantly in two individuals, for a net neutral effect at the population level.<br/> (<a href="https://doi.org/10.1101/2021.01.06.20248960" class="lit_link">Haynes et al. (2021)</a>)</span></li>
</ul></div>
<div class="acknowledgement">Automatically generated using text2ui script and data from <a href="https://github.com/nodrogluap/pokay">Pokay</a></div>
</body>
</html>
